Netherlands· NL-0588dd347960
Celsentri 300 mg, filmomhulde tabletten
A maraviroc product containing maraviroc, registered in Netherlands by ViiV healthcare B.V.. The same ATC class is registered in 15 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Maraviroc is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AX09 (maraviroc), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Maraviroc · ATC J05AX09
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of maraviroc costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), the median price runs from $25.28 in France to $84.16 in United States — a ×3.3 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Maraviroc · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- US United States$84.16 (acquisition cost)
- CH Switzerland$55.16
- FR France$25.28
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- MARAVIROC
- Manufacturer
- ViiV healthcare B.V.
- Country
- Netherlands (NL)
- ATC code
- J05AX09
- ATC class
- Maraviroc
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/07/418
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
143 interactions on record for maraviroc.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Maraviroc · interactions on record
143 records
- 14 severe
- 129 moderate
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- CeritinibL01ED02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Maraviroc in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesMaravirocNavinta LLC
- CzechiaCELSENTRIViiV Healthcare BV, Amersfoort
- SpainCELSENTRI 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULAViiv Healthcare B.V.
- FinlandCELSENTRIViiV Healthcare BV
- FranceCELSENTRI 300 mg, comprimé pelliculéVIIV HEALTHCARE UK (ROYAUME-UNI)
- SwedenCELSENTRI 300 mg Filmdragerad tablettViiV Healthcare BV
- IrelandCelsentri 300 mg Film-coated tabletViiV Healthcare BV
- SwitzerlandCelsentri
Authorised across Europe · EMA
The same active substance is authorised in 10 EEA countries. Names it is sold under:
- Austria · Maraviroc
- Germany · Maraviroc, Maraviroc Amarox
- Spain · Maraviroc Tarbis, Maraviroc Waymade
- France · Maraviroc, Maraviroc Amarox
- United Kingdom (Northern Ireland) · Maraviroc Amarox Limited, Maraviroc Waymade
- Iceland · Celsentri
- Italy · Maraviroc Waymade
- Liechtenstein · Celsentri
- Norway · Celsentri
- Portugal · Maraviroc
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e2fe5da4-3b0d-464c-acf2-5d27ee7d2e5c GET /v1/drugs/e2fe5da4-3b0d-464c-acf2-5d27ee7d2e5c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/celsentri-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Maraviroc",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp73658",
"excipients": [
"CALCIUMWATERSTOFFOSFAAT 0-WATER (E 341)",
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"INDIGOKARMIJN ALUMINIUMLAK (E 132)",
"LECITHINE, SOYA (E 322)",
"MACROGOL 3350",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMZETMEELGLYCOLAAT",
"POLYVINYLALCOHOL (E 1203)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"MARAVIROC"
],
"leaflet_url": null,
"authorised_at": "2007/09/17",
"procedure_number": "EMEA/H/C/000811",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/07/418",
"additional_monitoring": "N"
}See everything about maraviroc.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.